Literature DB >> 11084678

Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector.

I Strobel1, M Krumbholz, A Menke, E Hoffmann, P R Dunbar, A Bender, G Hobom, A Steinkasserer, G Schuler, R Grassmann.   

Abstract

Dendritic cells (DCs) are the most potent inducers of immune reactions. Genetically modified DCs, which express tumor-associated antigens (TAA), can efficiently induce antitumor immunity and thus have a high potential as tools in cancer therapy. The gene delivery is most efficiently achieved by viral vectors. Here, we explored the capacity of influenza virus vectors to transduce TAA genes. These viruses abortively infect DCs without interfering with their antigen-presenting capacity. In contrast to other viruses used for DC transduction, influenza viruses can be efficiently controlled by antiviral pharmaceuticals, lack the ability to integrate into host chromosomes, and fail to establish persistent infections. Genes encoding a melanoma-derived TAA (MAGE-3), or the green fluorescence protein (GFP), were introduced into a high-expression avian influenza virus vector. Monocyte-derived mature DCs infected by these recombinants efficiently produced GFP or MAGE-3. More than 90% of the infected DCs can express a transduced gene. Importantly, these transduced DCs retained their characteristic phenotype and their potent allogeneic T cell stimulatory capacity, and were able to stimulate MAGE-3-specific CD8(+) cytotoxic T cells. Thus influenza virus vectors provide a highly efficient gene delivery system in order to transduce human DCs with TAA, which consequently stimulate TAA-specific T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084678     DOI: 10.1089/104303400750035735

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.

Authors:  Tokiko Watanabe; Shinji Watanabe; Gabriele Neumann; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

3.  Recombinant lambda-phage nanobioparticles for tumor therapy in mice models.

Authors:  Amir Ghaemi; Hoorieh Soleimanjahi; Pooria Gill; Zuhair Hassan; Soodeh Razeghi M Jahromi; Farzin Roohvand
Journal:  Genet Vaccines Ther       Date:  2010-05-12

4.  Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.

Authors:  Kyoko Shinya; Yutaka Fujii; Hiroshi Ito; Toshihiro Ito; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Nuclear localization of avian polyomavirus structural protein VP1 is a prerequisite for the formation of virus-like particles.

Authors:  Reimar Johne; Hermann Müller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.

Authors:  Clay L Efferson; Jeanne Schickli; Byung Kyum Ko; Kouichiro Kawano; Sara Mouzi; Peter Palese; Adolfo García-Sastre; Constantin G Ioannides
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 7.  Development and application of reverse genetic technology for the influenza virus.

Authors:  Ziquan Li; Liping Zhong; Jian He; Yong Huang; Yongxiang Zhao
Journal:  Virus Genes       Date:  2021-02-02       Impact factor: 2.332

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.